Pluripotent stem cell based gene therapy for hematological diseases

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 238-246

  Vanhee, Stijn ^a   Vandekerckhove, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Gene therapy; Hematological diseases; Hematopoiesis; HESC; IPSC; Pluripotent stem cells; Stem cells; Tailored nucleases

Indexed keywords

COMPLEMENTARY DNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DISEASE SEVERITY; DNA HELIX; DNA REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR RECOGNITION; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; STEM CELL GENE THERAPY; TRANSCRIPTION REGULATION; GENE EDITING; GENE THERAPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INDUCED PLURIPOTENT STEM CELL; LENTIVIRINAE; PROCEDURES; TRANSPLANTATION;

GENE EDITING; GENETIC THERAPY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LENTIVIRUS;

EID: 84952637478     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.08.022     Document Type: Review

References (67)

1. Aiuti A., Biasco L., Scaramuzza S., Ferrua F., Cicalese M.P., Baricordi C., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341(6148):1233151.
2. Astrakhan A., Sather B.D., Ryu B.Y., Khim S., Singh S., Humblet-Baron S., et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012, 119(19):4395-4407.
3. Ban H., Nishishita N., Fusaki N., Tabata T., Saeki K., Shikamura M., et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(34):14234-14239.
4. Boztug K., Schmidt M., Schwarzer A., Banerjee P.P., Diez I.A., Dewey R.A., et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 2010, 363(20):1918-1927.
5. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(5954):818-823.
6. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., De Coene C., Selz F., Le Deist F., et al. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells. Blood 1996, 88(10):3901-3909.
7. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467(7313):318-322.
8. Chadwick K., Wang L., Li L., Menendez P., Murdoch B., Rouleau A., et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 2003, 102(3):906-915.
9. Choi J., Costa M.L., Mermelstein C.S., Chagas C., Holtzer S., Holtzer H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(20):7988-7992.
10. Choi K.D., Vodyanik M.A., Slukvin I.I. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors. J. Clin. Invest. 2009, 119(9):2818-2829.
11. Doulatov S., Vo L.T., Chou S.S., Kim P.G., Arora N., Li H., et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell 2013, 13(4):459-470.
12. Dowey S.N., Huang X., Chou B.K., Ye Z., Cheng L. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nat. Protoc. 2012, 7(11):2013-2021.
13. Evseenko D., Zhu Y., Schenke-Layland K., Kuo J., Latour B., Ge S., et al. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(31):13742-13747.
14. Focosi D., Amabile G., Di Ruscio A., Quaranta P., Tenen D.G., Pistello M. Induced pluripotent stem cells in hematology: current and future applications. Blood Cancer J. 2014, 4:e211.
15. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31(7):397-405.
16. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004, 364(9452):2181-2187.
17. Gaur M., Kamata T., Wang S., Moran B., Shattil S.J., Leavitt A.D. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J. Thrombosis Haemostasis 2006, 4(2):436-442.
18. Genovese P., Schiroli G., Escobar G., Di Tomaso T., Firrito C., Calabria A., et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014, 510(7504):235-240.
19. Haase A., Olmer R., Schwanke K., Wunderlich S., Merkert S., Hess C., et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5(4):434-441.
20. Hacein-Bey H., Cavazzana-Calvo M., Le Deist F., Dautry-Varsat A., Hivroz C., Riviere I., et al. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 1996, 87(8):3108-3116.
21. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
22. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118(9):3132-3142.
23. Hacein-Bey-Abina S., Pai S.Y., Gaspar H.B., Armant M., Berry C.C., Blanche S., et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2014, 371(15):1407-1417.
24. Hockemeyer D., Soldner F., Beard C., Gao Q., Mitalipova M., DeKelver R.C., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 2009, 27(9):851-857.
25. Hockemeyer D., Wang H., Kiani S., Lai C.S., Gao Q., Cassady J.P., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 2011, 29(8):731-734.
26. Hou Z., Zhang Y., Propson N.E., Howden S.E., Chu L.F., Sontheimer E.J., et al. Efficient genome engineering in human pluripotent stem cells using casfrom Neisseria meningitidis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(39):15644-15649.
27. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 2008, 118(9):3143-3150.
28. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142(3):375-386.
29. Kamel-Reid S., Dick J.E. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988, 242(4886):1706-1709.
30. Kennedy M., D'Souza S.L., Lynch-Kattman M., Schwantz S., Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 2007, 109(7):2679-2687.
31. Kennedy M., Awong G., Sturgeon C.M., Ditadi A., LaMotte-Mohs R., Zuniga-Pflucker J.C., et al. T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep. 2012, 2(6):1722-1735.
32. Kerre T.C., De Smet G., De Smedt M., Zippelius A., Pittet M.J., Langerak A.W., et al. Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells. Blood 2002, 99(5):1620-1626.
33. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4(6):472-476.
34. Kyba M., Perlingeiro R.C., Daley G.Q. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002, 109(1):29-37.
35. Ledran M.H., Krassowska A., Armstrong L., Dimmick I., Renstrom J., Lang R., et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 2008, 3(1):85-98.
36. Mali P., Aach J., Stranges P.B., Esvelt K.M., Moosburner M., Kosuri S., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 2013, 31(9):833-838.
37. Mandal P.K., Ferreira L.M., Collins R., Meissner T.B., Boutwell C.L., Friesen M., et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014, 15(5):643-652.
38. Meng X., Neises A., Su R.J., Payne K.J., Ritter L., Gridley D.S., et al. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol. Ther. 2012, 20(2):408-416.
39. Menon T., Firth A.L., Scripture-Adams D.D., Galic Z., Qualls S.J., Gilmore W.B., et al. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell 2015, 16(4):367-372.
40. Merling R.K., Sweeney C.L., Choi U., De R., avin S.S., Myers T.G., Otaizo-Carrasquero F., et al. Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 2013, 121(14):e98-107.
41. Nagy A., Rossant J., Nagy R., Abramow-Newerly W., Roder J.C. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(18):8424-8428.
42. Ng E.S., Davis R.P., Azzola L., Stanley E.G., Elefanty A.G. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 2005, 106(5):1601-1603.
43. O'Leary T., Heindryckx B., Lierman S., Van der Jeught M., Duggal G., De Sutter P., et al. Derivation of human embryonic stem cells using a post-inner cell mass intermediate. Nat. Protoc. 2013, 8(2):254-264.
44. Ohmine S., Dietz A.B., Deeds M.C., Hartjes K.A., Miller D.R., Thatava T., et al. Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. Stem Cell Res. Ther. 2011, 2(6):46.
45. Pereira C.F., Chang B., Qiu J., Niu X., Papatsenko D., Hendry C.E., et al. Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell 2013, 13(2):205-218.
46. Prasad V.K., Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br. J. Haematol. 2010, 148(3):356-372.
47. Qiu C., Olivier E.N., Velho M., Bouhassira E.E. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood 2008, 111(4):2400-2408.
48. Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., et al. Double nicking by RNA-guided CRISPR Casfor enhanced genome editing specificity. Cell 2013, 154(6):1380-1389.
49. Riddell J., Gazit R., Garrison B.S., Guo G., Saadatpour A., Mandal P.K., et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell 2014, 157(3):549-564.
50. Salavoura K., Kolialexi A., Tsangaris G., Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008, 28(2B):1263-1269.
51. Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336(6077):86-90.
52. Sommer A.G., Rozelle S.S., Sullivan S., Mills J.A., Park S.M., Smith B.W., et al. Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J. Visualized Exp. 2012, 68.
53. Szabo E., Rampalli S., Risueno R.M., Schnerch A., Mitchell R., Fiebig-Comyn A., et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010, 468(7323):521-526.
54. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
55. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282(5391):1145-1147.
56. Tian X., Woll P.S., Morris J.K., Linehan J.L., Kaufman D.S. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 2006, 24(5):1370-1380.
57. Timmermans F., Velghe I., Vanwalleghem L., De Smedt M., Van Coppernolle S., Taghon T., et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J. Immunol. 2009, 182(11):6879-6888.
58. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology 2011, 50(Suppl. 5):v49-v59.
59. Vanhee S., De Mulder K., Van Caeneghem Y., Verstichel G., Van Roy N., Menten B., et al. In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis. Haematologica 2014.
60. Vodyanik M.A., Bork J.A., Thomson J.A., Slukvin I.I. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005, 105(2):617-626.
61. Wang L., Menendez P., Shojaei F., Li L., Mazurier F., Dick J.E., et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J. Exp. Med. 2005, 201(10):1603-1614.
62. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7(5):618-630.
63. Weintraub H., Tapscott S.J., Davis R.L., Thayer M.J., Adam M.A., Lassar A.B., et al. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc. Natl. Acad. Sci. U. S. A. 1989, 86(14):5434-5438.
64. Woll P.S., Martin C.H., Miller J.S., Kaufman D.S. Human embryonic stem cell-derived NK s acquire functional receptors and cytolytic activity. J. Immunol. 2005, 175(8):5095-5103.
65. Yu Q.C., Hirst C.E., Costa M., Ng E.S., Schiesser J.V., Gertow K., et al. APELIN promotes hematopoiesis from human embryonic stem cells. Blood 2012, 119(26):6243-6254.
66. Zimmermann A., Preynat-Seauve O., Tiercy J.M., Krause K.H., Villard J. Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev. 2012, 21(13):2364-2373.
67. van Rijn R.S., Simonetti E.R., Hagenbeek A., Hogenes M.C., de Weger R.A., Canninga-van Dijk M.R., et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003, 102(7):2522-2531.